Organization (Hospital)
National Guard Health Affairs
ClinicalTrials.gov lists National Guard Health Affairs as lead sponsor of 17 trials, counting the companies grouped under it. National Guard Health Affairs itself has 4 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers National Guard Health Affairs and 1 company grouped under it: 17 lead-sponsored trials (14 its own, 3 in the grouped companies) and 2 legal-entity registrations (1 its own, 1 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| Imam Abdulrahman Al Faisal Hospital | 3 | 1 |
Disease areas (10)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Breast Neoplasms | 4 |
| Lung Neoplasms | 3 |
| Anemia | 1 |
| Anemia, Sickle Cell | 1 |
| Aphasia | 1 |
Showing 5 of 10 disease areas.
Trials by start year as sponsor or collaborator (9)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2021 | 1 |
| 2016 | 3 |
| 2015 | 1 |
| 2014 | 1 |
| 2012 | 1 |
| 2011 | 1 |
| 2010 | 1 |
| 2009 | 4 |
| 2008 | 1 |
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (4)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Erlotinib | 1 |
| GEMCITABINE | 1 |
| Fludarabine monophosphate | 1 |
| TRASTUZUMAB | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 51 | 23 | 2025-12-16 |
Latest dated events (68)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-16 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-12-09 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2024-06-11 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2024-05-07 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 68 events.
Biomarker capability evidence (8)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| BRAF | Trial sponsor | Named in trial inclusion criteria |
| EGFR | Trial sponsor | Named in trial inclusion criteria |
| ERBB2 | Trial sponsor | Named in trial inclusion criteria |
| MUC16 | Trial sponsor | Named in trial inclusion criteria |
| BRAF | Trial sponsor | Mentioned in trial text |
Showing 5 of 8 evidence rows.
Biomarkers this organization publishes on (2)
Shown in this order: most publications first.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, active development programs, sponsor delivery record, journals published in, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, and clia clinical laboratory certificates.